- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01219348
IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (IDOvaccine)
IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.
Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.
Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis when locally advanced or metastasized, despite advances in surgery, chemo- and radiation therapy.
In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Copenhagen
-
Herlev, Copenhagen, Denemarken, 2730
- Center for Cancer ImmuneTherapy
-
-
Herlev, Copenhagen
-
Copenhagen, Herlev, Copenhagen, Denemarken, 2730
- Center for Cancer Immune Therapy, Dept. og Haematology/Oncology
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
1. Histological or cytological verified non small cell lung cancer 2. Metastatic or locally advanced incurable stage III-IV NSCLC 3. Patients need to be off chemotherapy treatment 4. Evaluable disease according to RECIST V. 1,1 criteria 5. Patients must be HLA-A2 positive 6. Patients > 18 years old 7. Performance status 0-1 8. Life expectancy of > 3 months 9. Acceptable bone marrow function, defined as
a. White blood cell count > 2,5 * 109 /l b. Neutrophil count> 1,5 * 109 /l c. Platelet count > 75 * 109/l 10. Creatinin measured < 2,5 * upper limit value 11. Acceptable liver function, defined as
- ASAT < 100 U/L
Bilirubin < 30 U/L 12. Women with child-bearing potential must have controlled s-hcg before inclusion 13. Patients must provide written informed concent before inclusion 13. Termination of chemotherapy treatment > 28 days before inclusion
14. Termination of radiotherapy treatment > 28 days before inclusion
15. Inclusion at least > 4 weeks after complicated gastric surgery
-
Exclusion Criteria:
- Other malignancies except from non-melanoma skin cancer in the previous 5 years until study inclusion
- Brain metastasis are allowed after radical excision, and if the patient at least 1 month afterwards is not in clinical or radiographic progression
- Patients with active gastric ulcer disease; patients taking antacid treatment can be included.
- Severe medical condition, severe asthma, severe COLD, severe arteriosclerosis or diabetic disease
- Acute or chronic infection (ie. HIV, hepatitis, tuberculosis)
- Severe allergic reaction or previous anaphylactic shock
- Autoimmune diseases (ie. autoimmune neutropenia/thrombopenia, hæmolytic anaemia, systemic lupus erythematosis, Sjøgrens disease, sclerodermia, Goodpastures syndrome, Addisons disease, active Graves disease)
- Pregnant or lactating women
- Psychiatric disease, which can influence compliance
- Known hypersensitivity towards the adjuvance Montanide, the Aldara creme, or adhesive tape.
- Treatment with immunosuppressive therapy (ie. dexamethasone, methotrexate)
- Treatment with other experimental therapy
- Treatment with other anti-cancer therapy, except from treatment of osteoporosis
No systemic chemotherapy, immunotherapy or radiation therapy (except locally) are allowed until 28 days before inclusion.
-
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Indeolamine 2,3 deoxygenase
To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
|
Vaccination every second week
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
evidence of toxicity
Tijdsspanne: 12 months
|
CTCAE = Common Terminology Criteria for Adverse Events v. 3.0 will be used for registration of toxicity
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
evaluation of immunological and clinical responses
Tijdsspanne: 18 months
|
immunological assays will be used to identify immunological responses.
CT scans will be used for evaluation of clinical responses.
|
18 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Trine Zeeberg Iversen, MD, Center for Cancer Immune Therapy
Publicaties en nuttige links
Algemene publicaties
- Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.
- Andersen MH. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase. Cancer Immunol Immunother. 2012 Aug;61(8):1289-97. doi: 10.1007/s00262-012-1234-4. Epub 2012 Mar 3.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LU 1006 - IDO
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op NSCLC
-
Shanghai Henlius BiotechVoltooid
-
The Netherlands Cancer InstituteAanmelden op uitnodiging
-
Centre Oscar LambretUniversity Hospital, LilleBeëindigd
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdVoltooid
-
Bio-Thera SolutionsVoltooid
-
Jiangsu Province Nanjing Brain HospitalWerving
-
TYK Medicines, IncWerving
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNog niet aan het wervenNSCLCDuitsland, Nederland
-
Beta Pharma, Inc.Voltooid
Klinische onderzoeken op IDO peptide vaccination
-
Herlev HospitalVoltooidKwaadaardig melanoom met uitzaaiingenDenemarken
-
University of California, DavisNational Cancer Institute (NCI); IO BiotechWervingFase 0a Blaaskanker AJCC v8 | Fase 0 is blaaskanker AJCC v8 | Stadium I blaaskanker AJCC v8 | Hoog risico niet-spierinvasief blaas urotheelcarcinoomVerenigde Staten
-
Richard D. CarvajalVoltooidGastro-intestinale stromale tumorenVerenigde Staten
-
Inge Marie SvaneWervingGemetastaseerd melanoomDenemarken
-
Technical University of MunichVoltooid
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)BeëindigdInoperabel hepatocellulair carcinoom | Stadium III hepatocellulair carcinoom AJCC v8 | Stadium IIIA Hepatocellulair carcinoom AJCC v8 | Stadium IV hepatocellulair carcinoom AJCC v8 | Stadium IVA Hepatocellulair carcinoom AJCC v8 | Stadium IVB Hepatocellulair carcinoom AJCC v8 | Stadium IIIB Hepatocellulair... en andere voorwaardenVerenigde Staten
-
Thomas Jefferson UniversityBristol-Myers SquibbActief, niet wervendStrottenhoofd | Plaveiselcelcarcinoom | Lip | Plaveiselcelcarcinoom van de mondholte | KeelholteVerenigde Staten
-
Ohio State University Comprehensive Cancer CenterWervingOntvanger van allogene hematopoëtische stamceltransplantatieVerenigde Staten
-
Northwestern UniversityNational Cancer Institute (NCI)Actief, niet wervend